Home | Back to newsletter main page

Case Comprehensive Cancer Center Newsletter

January 18, 2011

CASE CCC IN THE NEWS

Breakthroughs & Advances
Cleveland Magazine - December 2010
Vincent Tuohy isn't the sort of guy the medical community expected to make a major advance in cancer research... Pancreatic cancer is a particularly lethal disease. Dr. Jeffrey Hardacre, a surgical oncologist at University Hospitals Case Medical Center, cites sobering statistics...


MESSAGE FROM THE DIRECTOR

Brian J. Bolwell, MD Appointed Associate Director for the Taussig Cancer Institute

Dr. BolwellStan Gerson, MD, Director of the Case Comprehensive Cancer Center, announces the appointment of Brian J. Bolwell, MD as Associate Director for the Taussig Cancer Institute. Dr. Bolwell will join the senior leaders of the Cancer Center coordinating the overall cancer research effort of the 364 members of the Cancer Center who are faculty at CWRU, University Hospitals, and Cleveland Clinic.

In his position as Associate Director, Dr. Bolwell oversees the clinical research at the Taussig Cancer Institute and facilitates its coordination and integration with the scientific programs and clinical investigations taking place throughout the Cancer Center. Major elements of the clinical research program are efforts to increase investigator initiated clinical trials, overall accrual to clinical trials, and translational research with the basic science laboratories of the Taussig Cancer Institute.

Dr. Bolwell brings a wealth of experience to his current position. He received his BA from Harvard University and his medical degree from the CWRU School of Medicine. Following his internship and residency at University Hospitals of Cleveland, he did his fellowship in hematology and medical oncology at the Hospital of the University of Pennsylvania in Philadelphia. Dr. Bolwell joined the faculty of the Cleveland Clinic in 1987, became the director of the bone marrow transplant program in 1988, and joined the Cleveland Clinic Board of Governors in 2004. Dr. Bolwell has served as Chairman of the Department of Hematologic Oncology and Blood Disorders since 2006, and Vice Chief of Staff since 2009. He is Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and has been a member of the Case Comprehensive Cancer Center since its expansion to include the Cleveland Clinic in 2003. He has published approximately 150 papers in the areas of transplantation and hematologic malignancies, and is active in the clinical research programs in transplantation within the Stem Cell Program of the Cancer Center.


ANNOUNCEMENTS

Clifford Harding, MD, PhD, Named Chair of Pathology at CWRU School of Medicine and UHCMC

Dr. Harding Congratulations to Dr. Clifford Harding, who was recently named Chair of Pathology at the CWRU School of Medicine and UHCMC. Dr. Harding became the Interim Chair of the department in May 2008, and assumed his new post as Department Chair in late December. We wish Dr. Harding continued success in his position.

More


MARK YOUR CALENDARS

Breast Cancer Retreat

The Cancer Center Breast Cancer Retreat is scheduled for Wednesday, February 9 at 9 am in the George S. Dively Building, Room 214. Further details and retreat agenda will be posted soon.


FUNDING OPPORTUNITIES

Cancer Research Institute Investigator Award

The Cancer Research Institute (CRI) is accepting applications for its Investigator Award, which supports accomplished assistant professors undertaking their first independent investigations in cancer immunology or general immunology. Candidates for the investigator award must hold a doctoral degree and be a tenure-track Assistant Professor at the time of award activation. CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools and research centers in the United States or abroad.

Deadline: March 1

Interinstitutional Basic, Clinical and Translational Research Projects in Cancer

The Case CCC will provide seed money to foster collaborations and promote and increase institution-wide capacity and competitiveness in basic, clinical or translational research that is aligned with the Cancer Center Scientific Programs and spans the institutions of the Case CCC. 2-3 awards of $75,000 - $100,000 will be made.

Faculty at all levels with interests in cancer research are encouraged to apply. Proposals require a minimum of two PIs: one from Case/UH and one from Cleveland Clinic. Proposals must involve new collaborative work with no joint publications or grants related to the current project. Applications will be submitted through http://webgrants.case.edu.

Deadline: TODAY, January 18, 2011

Complete information is available on the Cancer Center website.


ANNOUNCEMENTS

iMedRIS Training

New cancer research protocols requiring IRB review will be submitted, reviewed and stored electronically using the Case Cancer IRB electronic, web-based submission and review database provided by iMedRIS™ Data Corporation.

Part 4 (How to Respond to Stipulations) and Part 5 (How to submit Amendments) of the iMedRIS™ training sessions will be offered January through February. All interactive training will be accessible online using Adobe Acrobat Connect and telephone conference line and can be accessed at personal workstations.

For more information or to download training guides, please visit the iRIS Training Page. To register, please contact Mariesa Malinowski or Mark Tennant.

Clinical Assay Development Program (CADP)

The NIH has recently unveiled a new program, the Clinical Assay Development Program (CADP), designed to provide support and expertise to aid in the transition of predictive or prognostic cancer research assays to clinically validated, robust, "CLIA-approved" assays. This program is similar in scope and design to the RAID program for drug development.

The assay to be developed must measure predictive or prognostic markers, assays measuring diagnostic markers will not be considered for this program. The primary biospecimens to be utilized will be archived, formalin fixed, paraffin embedded tissues, however, assays utilizing other biospecimens will be acceptable if they are sufficiently compelling. One important eligibility criterion requires that the assay must be able to be performed with instrumentation and techniques available in standard clinical labs.

The deadline for the first round of applications is January 21.

For additional information or to request assistance in development of an application, please contact: John Pink (jrp16@cwru.edu), Director, Translational Research Core Facility, Case Comprehensive Cancer Center.

Details on the CADP are also available at http://cancer.case.edu/notices/files/CADPInfo.pdf

EVENTS

calendar

**All events are open to anyone interested in attending

January 17

Martin Luther King Day


January 18

Taussig Cancer Institute Core Curriculum Series
Stephen Smith, MD
Associate Staff, Hematologic Oncology and Blood Disorders
Cleveland Clinic
Topic: Follicular Lymphoma
12 pm R3-002 Cleveland Clinic


January 19

Developmental Therapeutics Program meeting canceled

Hematology and Oncology Division Research Conference canceled

11th Annual ASH Review
8 am - 3:30 pm The Ritz Carlton

Department of Immunology Seminar
Jaroslaw Maciejewski, MD, PhD
Professor, Hematology & Medical Oncology
CWRU/ Cleveland Clinic
Topic: TET2 Mutations and DNA Hydroxymethylation
12 pm NC1-202 Cleveland Clinic


January 20

Special Cancer Center Seminar Series
Gerard Blobe, MD, PhD
Associate Professor, Medicine, Pharmacology, and Cancer Biology
Duke University
Topic: The Type III TGF-beta Receptor Suppresses Cancer Progression
3 pm BRB 105

Aging-Cancer-Energetics Seminar
Linda Francis, PhD
Fellow, Prevention Research Education Postdoctoral (PREP) Training Program
Senior Research Associate
MetroHealth Medical Center
Topic: Bereavement in Family Caregiving in Advanced Cancer
4 pm BRB 732


January 21

Hematology/Oncology Fellows
Scott Sommers, MD
Fellow, Div. of Hem/Onc
CWRU/ UH
Topic: Management of Chronic Phase Chronic Myelogenous Leukemia: Are We Witnessing the Death of the Magic Bullet?
8 am Wearn 137

Taussig Cancer Institute Grand Rounds
Thomas Hutchinson, MD
Professor, Department of Medicine
McGill University
Topic: Whole Person Care: Encompassing the Two Faces of Medicine
8 am R3/002-003 Cleveland Clinic

Cancer Center Seminar Series
Matthew Vander Heiden, PhD
Assistant Professor, Biology
Koch Institute for Integrative Cancer Research at MIT
Instructor, Medicine
Dana-Farber Cancer Institute/ Harvard Medical School
Topic: Metabolic Alteration in Tumor Cells
12 pm BRB 105

Cell Biology Seminar Series
Takao Sakai, MD, PhD
Assistant Professor, Biomedical Engineering
CWRU/ Cleveland Clinic
Topic: TBD
10 am NC1-202 Cleveland Clinic

Cancer Center Research in Progress Seminar
Shigemi Matsuyama, DVM, PhD
Assistant Professor, Medicine-Hem/Onc
CWRU/ UH
Topic: Cell Penetrating Peptides: Mechanism of Cell Entry and Application for Drug (Protein and Gene) Delivery
4 pm WRB 3-136

 

Case CCC Calendar

LRI Calendar


UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS

Breast Cancer Detection and Management: Issues for 2011
May 20
Hilton Cleveland East
Details to follow

8th International Conference of the Society for Integrative Oncology
November 10-12
InterContinental Hotel Cleveland
Details to follow

ADDITIONAL UPCOMING SEMINARS & EVENTS

Active Living Research Annual Conference
February 22-24, 2011
San Diego, CA
Call for Abstracts Deadline: August 6
Details

14th Annual Meeting of the Translational Research Cancer Centers Consortium 2011
February 24-26
Seven Springs Mountain Resort, Seven Springs, PA
Details

Multilevel Interventions in Health Care: Building the Foundation for Future Research Goals
March 4-5, 2011
Las Vegas, Nevada
Details

4th Annual Biospecimen Research Network (BRN) Symposium: Advancing Cancer Research Through Biospecimen Science
March 28-29, 2011
Bethesda North Marriott Hotel & Conference Center in Bethesda, Maryland
Details

2011 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting
April 27-29, 2011
Omni Shoreham in Washington, DC
Abstract Deadline: December 16
Details

International Society for Stem Cell Research (ISSCR) Annual Meeting
June 15-18
Toronto, Canada
Details

Cancer Health Disparities Summit 2011
July 13-15, 2011
Bethesda North Marriott Hotel in Rockville, Maryland
Details

Shared Instrumentation Grant - DEXA Scanner

Message from Dr. Nathan Berger

As part of the Case CCC, we anticipate responding to NIH Shared Instrument Grant (S1O) PAR-11-081 with a request for a Dual-Energy X-ray Absorption (DEXA) Scanner. DEXA Scanning provides state-of-the-art technology for measurement of lean body-muscle mass, fat mass and bone density. We will apply for a patient level instrument and if enough interest exists, we will also apply for an instrument to perform the same measurements in small animals. Policy permitting, we are also considering applying for a Direct Segmental Multi-Frequency Bioelectrical Impedance Apparatus to perform repetitive measurements of body composition.

As you know, these awards are made to support the needs of groups of NIH funded investigators. Accordingly, I am requesting that any NIH funded investigators who anticipate using DEXA Scanning as a research tool notify me of their intent and send to me by January 20 a description of their research and need for these measurements (no more than 1 page), along with name, title and description of relevant NIH grant funding and an updated copy of your biosketch in NIH format. Please send all materials to sxw12@case.edu.

Please pass this email along to any other faculty member who might be interested. I would be happy to talk to anyone who wants further clarification.


NCI CANCER BULLETIN

January 11, 2011

News
Featured Article: Continued Shortage of Chemotherapy Drugs Causing Concern

Another JAK2 Inhibitor Shows Promise against Myelofibrosis

Treatment for Ductal Carcinoma In Situ Varies Substantially

Major Gene Mutation Identified in Lymphoma Tumors

Commentary
Inside NCI: A Conversation with Dr. Barry Kramer about Cancer Screening

In Depth
Preserving Fertility While Battling Cancer

Featured Clinical Trial: Comparing First-Line Therapies for Mucinous Ovarian or Fallopian Tube Cancer

The Kimmel Cancer Center at Thomas Jefferson University

Updates
Notes

PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES

Avon Foundation Breast Cancer Research Program
Cycle 1 LOI Deadline: January 21
Cycle 1 Full Proposal Deadline: March 11

Prostate Cancer Foundation (PCF)-Honorable A. David Mazzone Special Challenge Award Research Program
Deadline: February 24

AICR Research Grant Program
External LOI Deadline: January 25
External Full Application Deadline: May 2

AICR Investigator Initiated Grants (IIGs)
LOI Deadline: January 25
Full Application Deadline: May 2

AICR Matching Grants
LOI Deadline: January 25
Full Application Deadline: May 2

AICR Postdoctoral Awards (PDAs)
LOI Deadline: January 25
Full Application Deadline: May 2

ACS Joseph S. Silber Student Research Fellowship
Deadline: January 28

2011 Lasker Medical Research Awards
Nomination Deadline: February 1

2011 Jane Coffin Childs Memorial Fund for Medical Research Fellowship Awards
Deadline: February 1


Leukemia Research Foundation
Deadline: February 15

ACS Cancer Research Fellowship
Deadline: February 16

James S. McDonnell Foundation 21st Century Science Research Awards
Deadline: March 15

Avon Foundation Breast Cancer Research Program
Cycle 2 LOI Deadline: May 6
Cycle 2 Full Proposal Deadline: July 5

Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
Deadline: Open

AACR Scholar-in-Training Awards - Other Conferences and Meetings
Deadline: Open

International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
Application Deadline: Open

NCI Short-Term Scientist Exchange Program
Application Deadline: Open

James S. McDonnell Foundation Collaborative Activity Awards
Application Deadline: Open


NIH BULLETIN – Notices and Funding Opportunities

NIH Policy on Late Submission of Grant Applications (NOT-OD-11-035)

Request for Information (RFI): Interagency Breast Cancer and Environmental Research Coordinating Committee (NOT-ES-11-006)

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216-844-8317 phone
216-844-7832 fax
gillian.irwin@case.edu

HELP US HELP YOU!

If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to gillian.irwin@case.edu.